pharma · Alopecia areata · Multiple myeloma
First Biotech (Australia)
Pfizer Australia Pty Ltd
First Biotech (Australia) clinical programs — 126 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
- Founded
- 2017
- Employees
- 2
- Programs
- 126
- Drugs
- 208
- Patents
- 0
First Biotech (Australia) projects
126 ClinicalTrials.gov programs sponsored by First Biotech (Australia).
First Biotech (Australia) has 126 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
C4551007
Pfizer Australia Pty Ltd
locally advanced or metastatic ER+/HER2- breast cancer
1 trial -
C4551010
Pfizer Australia Pty Ltd
locally advanced or metastatic HR+/HER2- breast cancer
1 trial -
C4891037
Pfizer Australia Pty Ltd
ER+/HER2- breast cancer
1 trial -
C4891038
Pfizer Australia Pty Ltd
ER+/HER2- Breast Cancer
1 trial -
C4921002
Pfizer Australia Pty Ltd
Heart failure
1 trial -
C4921008
Pfizer Australia Pty Ltd
Heart Failure
1 trial -
C4951092
Pfizer Australia Pty Ltd
Migraine with or without aura
1 trial -
C5091010
Pfizer Australia Pty Ltd
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
1 trial -
C5091029
Pfizer Australia Pty Ltd
Coronavirus disease 2019
1 trial -
C5171002
Pfizer Australia Pty Ltd
heart failure with preserved ejection fraction
1 trial -
C5381001
Pfizer Australia Pty Ltd
clonal hematopoiesis
1 trial -
C5381002
Pfizer Australia Pty Ltd
Clonal hematopoiesis
1 trial -
C5541002
Pfizer Australia Pty Ltd
Obesity, Overweight
1 trial -
C5661001
Pfizer Australia Pty Ltd
IgA nephropathy
1 trial -
C5671001
Pfizer Australia Pty Ltd
CCI
1 trial -
C5911001 - SGN-CD25V
Pfizer Australia Pty Ltd
Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)
1 trial -
C5951001
Pfizer Australia Pty Ltd
advanced solid tumors
1 trial -
C5961001
Pfizer Australia Pty Ltd
RSV (Respiratory Syncytial Virus)
1 trial -
C6001001
Pfizer Australia Pty Ltd
Non-muscle invasive bladder cancer (NMIBC)
1 trial -
C6081001
Pfizer Australia Pty Ltd
KRAS mutated advanced solid tumors
1 trial -
C6341001
Pfizer Australia Pty Ltd
Rheumatoid arthritis and Systemic Lupus Erythematosus
1 trial -
Etrasimod Arginine Blue
Pfizer Australia Pty Ltd
Ulcerative Colitis and immune-mediated inflammatory disorders
1 trial -
PF-07868489 Placebo, PF-07868489
Pfizer Australia Pty Ltd
Pulmonary Arterial Hypertension
1 trial -
A8081075
Pfizer Australia Pty Ltd
This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
1 trial -
B7471015
Pfizer Australia Pty Ltd
VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA
1 trial -
C4221026
Pfizer Australia Pty Ltd
Solid tumors
1 trial -
C4951004/BHV3000-406
Pfizer Australia Pty Ltd
Migraine attacks with or without aura
1 trial -
C4951012/BHV3000-407
Pfizer Australia Pty Ltd
migraine headaches with or without aura
1 trial -
DAN-RSV
Pfizer Australia Pty Ltd
RSV-infection
1 trial -
LORLATINIB
Pfizer Australia Pty Ltd
Lung cancer
1 trial
Frequently asked questions
How many clinical projects does First Biotech (Australia) have?
126 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.